However, they also reported that a single dose of injection can only delay but cannot prevent the progression of the disease because of the exhaustion of transferred 287-CAR-T.539 HLA-DR1 CAR CD8+ T cells are designed to target the pathogenic autoreactive CD4+ T cells and restrict RA development.540 In addition, it has been reported that the engineered CAR-T cells produced by importing mRNA encoding InsB15-23/β2m/CD3-ζ into the CD8+ T cell can target the pathogenic CD8+ T cells and it offers a new approach to treat T1D diseases.541. The gene discussed is CD4; the disease is type 1 diabetes mellitus.